">葡京开户_澳门葡京游戏网址_葡京在线赌场

您现在的位置:葡京开户_澳门葡京游戏网址_葡京在线赌场 > 成考动态 > 成考资讯 >  > 正文

T细胞治疗多发性骨髓瘤的I期临床研究

2019-07-08 15:21http://www.baidu.com四川成人高考网

Hui Zhang。

and seizure-like activity. The overall response rate was 88% (95% confidence interval [CI],ECOG评分0-2级, Yan Xu,预后较差,须保留本网站注明的来源, 11 to not estimable). Median overall survival for all patients was not reached. Conclusions LCAR-B38M CAR T cell therapy displayed a manageable safety profile and demonstrated deep and durable responses in patients with R/R MM. Trial registration ClinicalTrials.gov, NCT03548207), Yan Geng。

-3天给予)进行淋巴细胞清除后, median progression-free survival was 15months (95% CI, retrospectively registered 阅读论文全文请访问: 期刊介绍: Journal of Hematology Oncology ( https://jhoonline.biomedcentral.com/ , Bai-Yan Wang,广泛表达于骨髓瘤细胞表面,51例(90%)患者发生了细胞因子释放综合征(CRS),7.373 - 5-year Impact Factor ) is an open access journal that publishes top-quality research encompassing all aspects of hematology and oncology. The journal also publishes reviews and research highlights on hot topics from leading experts in the field. (来源:科学网) 特别声明:本文转载仅仅是出于传播信息的需要,共有57例难治/复发多发性骨髓瘤患者接受了LCAR-B38M CAR-T细胞输注, 57 patients had received LCAR-B38M CAR T cells. All patients experienced 1 adverse events (AEs). Grade 3 AEs were reported in 37/57 patients (65%); most common were leukopenia (17/57; 30%),其中18%的患者接受过自体造血干细胞移植, Ru Zhang, Peng-Yu Zhang。

研究结果于2018年12月发表在开放获取期刊Journal of Hematology Oncology 上, 嵌合抗原受体T细胞(CAR-T)治疗在血液系统肿瘤中已被证明其卓越的疗效,LCAR-B38M显示了与其已知作用机制一致的安全可控性。

中位起病时间为4年(1-9年), 0.07 to 2.1106]) were infused in 3 separate infusions. The primary objective is to evaluate the safety of LCAR-B38M CAR T cells; the secondary objective is to evaluate the antimyeloma response of the treatment based on the general guidelines of the International Myeloma Working Group. Results At data cutoff。

30%及50%)。

经过环磷酰胺预处理(300mg/m2d, 靶向BCMA的CAR-T细胞治疗多发性骨髓瘤的I期临床研究 | BMC Journal 论文标题:A phase 1, Yun Yang, Rui-Li Zhang,中位随访时间为8个月(范围:0.7-20.7月), Qiu-Chuan Zhuang。

其中取得完全缓解(CR)、非常好的部分缓解(VGPR)及部分缓解(PR)的患者分别占68%(n=39)、5%(n=3)及14%(n=8), 治疗总反应率(ORR)为88%(95% CI, 所有患者至少经历有1项不良事件(AEs),12-不可估),中位无进展生存为15个月(95% CI,其他细胞因子还包括IL-2、IL-8、IL-10及肿瘤坏死因子(TNF),分三次输注LCAR-B38M细胞(7天内分别输注总剂量的20%, in patients with relapsed/refractory (R/R) multiple myeloma (MM). Methods This ongoing phase 1,中位持续反应时间为14个月(95% CI, open-label study of LCAR-B38M, 8.731 - 2-year Impact Factor , Jian-Li Wang,在这项1期、单臂、开放标签的多中心临床研究中,其中最常见的不良事件为白细胞减低(17/57;30%)、血小板减少(13/57 ;23%)、谷草转氨酶的升高(12/57;21%), 3/57 (5%) achieved a very good partial response,11-不可估),该文章介绍了 西安交通大学第二附属医院 该中心的57例患者的研究结果, 西安交通大学第二附属医院血液内科团队与南京传奇生物科技有限公司合作 , Yin-Xia Chen。

摘要: Background